采用利拉鲁肽联合二甲双胍治疗2型糖尿病临床疗效研究

Study on the Clinical Efficacy of Liraglutide Combined with Metformin in the Treatment of Type 2 Diabetes

目的分析利拉鲁肽联合二甲双胍治疗2型糖尿病的临床效果,并分析对患者血糖水平的影响。方法随机选取2020年7月—2021年6月于该院进行诊治的2型糖尿病患者60例,基于随机抽签方式对研究对象进行组别划分,分为参照组与研究组,每组30例。参照组对患者应用二甲双胍治疗,研究组对患者应用利拉鲁肽联合二甲双胍治疗,对两组患者血糖水平、胰岛素抵抗指数、炎症因子水平及临床治疗有效率进行比较。结果研究组患者空腹血糖、餐后2 h血糖、糖化血红蛋白以及胰岛素抵抗指数分别为(6.49±0.81)mmol/L、(8.46±1.01)mmol/L、(7.16±1.75)%、(2.02±0.58),明显优于参照组,差异有统计学意义(t=4.821、8.960、4.849、2.391,P<0.05);研究组患者肿瘤坏死因子-α、白介素-4、白介素-10分别为(5.22±1.07)、(3.04±0.51)、(6.46±1.17)ng/L,明显低于参照组,差异有统计学意义(t=2.806、3.093、2.962,P<0.05);研究组临床治疗有效率(96.66%)高于参照组,差异有统计学意义(χ^(2)=4.705,P=0.030)。结论 2型糖尿病患者应用利拉鲁肽联合二甲双胍治疗方式,可改善患者血糖水平与胰岛素抵抗指数,调节患者炎症因子状态,降糖效果理想。

Objective To analyze the clinical effect of liraglutide combined with metformin in the treatment of type 2 diabetes,and to analyze the effect on the patient’s blood glucose level. Methods Randomly selected 60 patients with type 2 diabetes who were diagnosed and treated in the hospital from July 2020 to June 2021. Based on the random lottery method, the study subjects were divided into groups and divided into reference group and study group, with 30 cases in each group. Patients in the reference group were treated with metformin, and the study group was treated with liraglutide combined with metformin. The blood glucose levels, insulin resistance index, inflammatory factor levels and clinical treatment efficiency of the two groups were compared. Results The fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin, and insulin resistance index of patients in the study group were(6.49±0.81)mmol/L,(8.46±1.01)mmol/L,(7.16±1.75)%,(2.02±0.58),respectively, significantly better than the reference group, the difference was statistically significant(t=4.821, 8.960, 4.849,2.391, P<0.05);the tumor necrosis factor-α, interleukin-4, and interleukin-10 of the study group were(5.22±1.07)ng/L,(3.04±0.51)ng/L,(6.46±1.17)ng/L, which were significantly lower than the reference group, the difference was statistically significant(t=2.806, 3.093, 2.962, P<0.05);the study group has clinical treatment efficiency(96.66%) was higher than the reference group, and the difference was statistically significant(χ^(2)=4.705, P=0.030). Conclusion The treatment of type2 diabetic patients with liraglutide combined with metformin can improve the patient’s blood glucose level and insulin resistance index, adjust the patient’s inflammatory factor status, and have an ideal hypoglycemic effect.